VYGR
Voyager Therapeutics, Inc.
There isn't enough reported data to score VYGR yet.
VYGR Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Weak | |
| Strong |
VYGR's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
VYGR PE Valuation
VYGR has no meaningful PE right now: it lost money over the past year.
VYGR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Decline | |
| -- | |
| Limited | |
| Low |
Analysts expect VYGR's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
VYGR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.74 | +$0.42 |
| Q2 2026 | -$1.81 | +$0.04 |
| Q1 2026 | -$1.98 | -$0.52 |
| Q4 2025 | -$2.04 | -$0.91 |
| Q3 2025 | -$2.16 | -466% |
| Q2 2025 | -$1.85 | -1256% |
| Q1 2025 | -$1.46 | -$1.29 |
| Q4 2024 | -$1.13 | -138% |
VYGR is still losing money, but less than at its worst: $1.74 per share over the past year, against $2.45 at its worst in late 2021.
VYGR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4M | -70% |
| Q2 2026 | $3.2M | -39% |
| Q1 2026 | $2.6M | -60% |
| Q4 2025 | $15.3M | +144% |
| Q3 2025 | $13.4M | -46% |
| Q2 2025 | $5.2M | -82% |
| Q1 2025 | $6.5M | -67% |
| Q4 2024 | $6.3M | -93% |
VYGR's revenue has slid since its 2023 peak: $4M last quarter, down 70% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -658% | -429 points |
| Q2 2026 | -834% | -130 points |
| Q1 2026 | -1167% | -631 points |
| Q4 2025 | -195% | +415 points |
| Q3 2025 | -229% | -173 points |
| Q2 2025 | -704% | -654 points |
| Q1 2025 | -536% | -453 points |
| Q4 2024 | -610% | -670 points |
VYGR's operating margin was −658% last quarter, down 429 points from the same quarter a year ago.
VYGR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$19.7M | +$11.6M |
| Q2 2026 | -$25.8M | +$8.5M |
| Q1 2026 | -$33.4M | +$5.1M |
| Q4 2025 | -$30.9M | -$16.2M |
| Q3 2025 | -$31.3M | -$3M |
| Q2 2025 | -$34.4M | -$1.8M |
| Q1 2025 | -$38.6M | -168% |
| Q4 2024 | -$14.7M | +$9.8M |
VYGR has burned cash in almost every quarter: −$110M over the past year, against −$119M the year before.
VYGR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.1% | +1.3M shares |
| 1 year | +5.1% | +3M shares |
| 3 years | +41% | +18M shares |
| 5 years | +64% | +24M shares |
| Available history | +72% | +25.9M shares |
VYGR has 62M diluted shares, up 5.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2022 | — |
VYGR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2024 | -8.0x | Net Cash |
| Q4 2023 | -0.5x | Net Cash |
| Q3 2023 | -1.4x | Net Cash |
| Q2 2023 | -2.6x | Net Cash |
| Q1 2023 | -2.7x | Net Cash |
| Q2 2021 | -10.6x | Net Cash |
| Q1 2021 | -3.9x | Net Cash |
| Q4 2020 | -3.4x | Net Cash |
VYGR has more cash than debt.
VYGR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 26.9 | Oversold |
| Stochastic | 4.6 | Oversold |
VYGR's weekly RSI is 27 (oversold) and its Stochastic is 5 (oversold).
VYGR PE vs Healthcare Sector
| Metric | VYGR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
VYGR has no meaningful PE right now: it lost money over the past year.
VYGR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.06 | 17% below |
| 20 week MA | $2.81 | 40% below |
| 50 week MA | $3.45 | 51% below |
| 100 week MA | $3.74 | 55% below |
| 200 week MA | $5.97 | 72% below |
VYGR is in a downtrend: it's below all five of its weekly moving averages, and 72% below its 200-week average.
VYGR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $13.9 | $7.98 | -43% |
| 2021 | $7.98 | $2.93 | -63% |
| 2022 | $2.93 | $5.56 | +90% |
| 2023 | $5.56 | $8.44 | +52% |
| 2024 | $8.44 | $5.74 | -32% |
| 2025 | $5.74 | $4.08 | -29% |
| 2026 YTD | $4.08 | $1.70 | -58% |
VYGR has finished lower in four of the last six years. It's down 58% so far in 2026.